위식도역류질환 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약제 유형별, 지역별, 부문별 예측(2025-2030년)

Gastroesophageal Reflux Disease Therapeutics Market Growth & Trends:

The global gastroesophageal reflux disease therapeutics market size is anticipated to reach USD 5.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 2.0% from 2025 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.

Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.

Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.

Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.

Gastroesophageal Reflux Disease Therapeutics Market Report Highlights:

• Antacids segment dominated the gastroesophageal reflux disease treatment market in 2024 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach.
• Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
• Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD.
• North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis

• 4.1. Drug Type Market Share, 2024 & 2030
• 4.2. Drug Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 4.4. Antacids
  • 4.4.1. Antacids Market, 2018 - 2030 (USD Million)
• 4.5. H2 Receptor Blockers
  • 4.5.1. H2 Receptor Blockers Market, 2018 - 2030 (USD Million)
• 4.6. Proton Pump Inhibitors (PPIs)
  • 4.6.1. Proton Pump Inhibitors (PPIs) Market, 2018 - 2030 (USD Million)
• 4.7. Pro-kinetic Agents
  • 4.7.1. Pro-kinetic Agents Market, 2018 - 2030 (USD Million)

Chapter 5. Gastroesophageal Reflux Disease Therapeutics Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Regulatory Framework
    • 5.4.2.3. Competitive Insights
    • 5.4.2.4. U.S. Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Regulatory Framework
    • 5.4.3.3. Competitive Insights
    • 5.4.3.4. Canada Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Regulatory Framework
    • 5.4.4.3. Competitive Insights
    • 5.4.4.4. Mexico Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Regulatory Framework
    • 5.5.2.3. Competitive Insights
    • 5.5.2.4. UK Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Regulatory Framework
    • 5.5.3.3. Competitive Insights
    • 5.5.3.4. Germany Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Regulatory Framework
    • 5.5.4.3. Competitive Insights
    • 5.5.4.4. France Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Regulatory Framework
    • 5.5.5.3. Competitive Insights
    • 5.5.5.4. Italy Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Regulatory Framework
    • 5.5.6.3. Competitive Insights
    • 5.5.6.4. Spain Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Norway
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Regulatory Framework
    • 5.5.7.3. Competitive Insights
    • 5.5.7.4. Norway Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Denmark
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Regulatory Framework
    • 5.5.8.3. Competitive Insights
    • 5.5.8.4. Denmark Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Sweden
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Regulatory Framework
    • 5.5.9.3. Competitive Insights
    • 5.5.9.4. Sweden Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Regulatory Framework
    • 5.6.2.3. Competitive Insights
    • 5.6.2.4. Japan Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Regulatory Framework
    • 5.6.3.3. Competitive Insights
    • 5.6.3.4. China Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Regulatory Framework
    • 5.6.4.3. Competitive Insights
    • 5.6.4.4. India Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. South Korea
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Regulatory Framework
    • 5.6.5.3. Competitive Insights
    • 5.6.5.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. Australia
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Regulatory Framework
    • 5.6.6.3. Competitive Insights
    • 5.6.6.4. Australia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Regulatory Framework
    • 5.6.7.3. Competitive Insights
    • 5.6.7.4. Thailand Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Regulatory Framework
    • 5.7.2.3. Competitive Insights
    • 5.7.2.4. Brazil Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Regulatory Framework
    • 5.7.3.3. Competitive Insights
    • 5.7.3.4. Argentina Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. MEA Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Regulatory Framework
    • 5.8.2.3. Competitive Insights
    • 5.8.2.4. South Africa Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Regulatory Framework
    • 5.8.3.3. Competitive Insights
    • 5.8.3.4. Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Regulatory Framework
    • 5.8.4.3. Competitive Insights
    • 5.8.4.4. UAE Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Regulatory Framework
    • 5.8.5.3. Competitive Insights
    • 5.8.5.4. Kuwait Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. AstraZeneca
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Eisai Co., Ltd.
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. GSK plc.
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Takeda Pharmaceutical Company Limited
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Ironwood
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Johnson & Johnson Services, Inc.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. SFJ Pharmaceuticals
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Sebela Pharmaceuticals
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Phathom Pharmaceuticals, Inc.
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Camber Pharmaceuticals, Inc.
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives